He Hai-Lang, Wang Dan, Tang Jie, Zhou Xian-Mei, Li Jian-Xin, Xu Ling
Department of Respiratory Medicine, Affiliated Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210029, China.
State Key Laboratory of Analytical Chemistry for Life Science and Collaborative Innovation Center of Chemistry for Life Sciences, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
Evid Based Complement Alternat Med. 2016;2016:3635209. doi: 10.1155/2016/3635209. Epub 2016 Sep 6.
Lung cancer is the leading cause of cancer-related deaths worldwide. Jin Fu Kang (JFK), an oral liquid prescription of Chinese herbal drugs, has been clinically available for the treatment of non-small cell lung cancer (NSCLC). Lymphangiogenesis is a primary event in the process of cancer development and metastasis, and the formation and migration of lymphatic endothelial cells (LECs) play a key role in the lymphangiogenesis. To assess the activity of stromal cell-derived factor-1 (SDF-1) and the coeffect of SDF-1 and vascular endothelial growth factor-C (VEGF-C) on the formation and migration of LECs and clarify the inhibitory effects of JFK on the LECs, the LECs were differentiated from CD34/VEGFR-3 endothelial progenitor cells (EPCs), and JFK-containing serums were prepared from rats. SDF-1 and VEGF-C both induced the differentiation of CD34/VEGFR-3 EPCs towards LECs and enhanced the LECs migration. Couse of SDF-1 and VEGF-C displayed an additive effect on the LECs formation but not on their migration. JFK inhibited the formation and migration of LECs, and the inhibitory effects were most probably via regulation of the SDF-1/CXCR4 and VEGF-C/VEGFR-3 axes. The current finding suggested that JFK might inhibit NSCLC through antilymphangiogenesis and also provided a potential to discover antilymphangiogenesis agents from natural resources.
肺癌是全球癌症相关死亡的主要原因。金复康（JFK）是一种中药口服液制剂，已在临床上用于治疗非小细胞肺癌（NSCLC）。淋巴管生成是癌症发展和转移过程中的一个主要事件，淋巴管内皮细胞（LEC）的形成和迁移在淋巴管生成中起关键作用。为了评估基质细胞衍生因子-1（SDF-1）的活性以及SDF-1与血管内皮生长因子-C（VEGF-C）对LEC形成和迁移的协同作用，并阐明JFK对LEC的抑制作用，从CD34/VEGFR-3内皮祖细胞（EPC）中分化出LEC，并从大鼠制备含JFK的血清。SDF-1和VEGF-C均诱导CD34/VEGFR-3 EPC向LEC分化并增强LEC迁移。SDF-1与VEGF-C联合对LEC形成显示相加作用，但对其迁移无相加作用。JFK抑制LEC的形成和迁移，其抑制作用很可能是通过调节SDF-1/CXCR4和VEGF-C/VEGFR-3轴。目前的研究结果表明，JFK可能通过抗淋巴管生成抑制NSCLC，也为从天然资源中发现抗淋巴管生成药物提供了潜力。
